U.S. market Open. Closes in 5 hours 28 minutes

VYNE | VYNE Therapeutics Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenue424.00K477.00K14.76M20.99M443.00K10.64M4.58M674.00KN/A
Cost of RevenueN/AN/A3.35M1.39M350.00KN/AN/AN/AN/A
Gross Profit424.00K477.00K11.41M19.60M93.00K10.64MN/AN/AN/A
Operating Expenses29.68M34.77M79.44M133.08M76.24M65.17M34.17MN/AN/A
Selling, General & Admin13.38M16.39M54.48M89.54M22.48M12.19M5.17M3.75M1.69M
Research & Development16.31M18.39M24.96M43.53M53.76M52.99M29.01M11.26M2.92M
Other Operating Expenses1.39M363.00K-135.00K1.11MN/AN/AN/AN/AN/A
Operating Income-29.26M-34.30M-68.03M-113.47M-76.24M-54.53M-29.59M-14.33M-4.61M
Other Expenses / Income1.39M363.00K-5.75M-142.35M2.54M3.09M517.00K264.00KN/A
Before Tax Income-27.87M-33.93M-73.78M-255.83M-73.70M-51.45M-29.08M-14.07M-4.61M
Income Tax Expenses580.00K13.00K-448.00K-258.00K-3.24M3.09MN/AN/AN/A
Net Income-28.45M-33.95M-73.33M-255.57M-70.46M-51.45M-29.08M-14.07M-4.61M
Interest ExpensesN/A-10.81M5.61M4.39M2.54M3.09MN/AN/AN/A
Basic Shares Outstanding10.27M3.19M2.86M1.80M471.39K300.95K286.04K2.56M2.88M
Diluted Shares Outstanding10.27M3.19M2.86M1.80M471.39K300.95K286.04K2.56M2.88M
EBITDA-29.26M-33.93M-68.17M-112.02M-76.24M-54.53M-29.07M-14.06M-4.61M
EBITDA Margin-6,900.47%-7,113.63%-461.99%-533.63%-17,210.38%-512.55%-634.40%-2,086.65%0.00%
EBIT-27.87M-44.74M-68.17M-251.44M-71.16M-45.27M-29.08M-14.07M-4.61M
EBIT Margin-6,573.58%-9,379.25%-461.99%-1,197.71%-16,064.11%-425.42%-634.57%-2,087.24%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙